S475
Clinical - Gynaecological
ESTRO 2026
association was observed between obesity and the incidence of acute radiodermatitis(p<0.001), enteritis(p<0.0001), and acute radiation cystitis(p=0.006). Subgroup analysis of obese patients revealed a significant increase in acute radiation enteritis in cases of lymph node dissection (p 0.049), associated chemotherapy (p0.005), and in the presence of other comorbidities (p 0.003). Acute radiodermatitis was also significantly increased in cases where chemotherapy was added (p 0.0002). Age,tumor stage,and dose received were not significantly associated with toxicities. Conclusion: The results of our study highlight the negative impact of obesity on tolerance to pelvic radiotherapy in these patients, which is consistent with the literature[2–3].Hence the importance of recommending systematic weight loss programs for oncological therapeutic purposes with strict monitoring during radiotherapy. References: 1.Fernandez S, Marzo M, Sánchez M, et al. Impact Of Visceral Obesity On The Prognosis Of Patients With Endometrial Cancer. International Journal of Gynecological Cancer. 2025;35(2). doi:10.1016/j.ijgc.2024.1006832.Abdallah HH, Tbessi S, Bouguerra F, et al. 448 Correlation between obesity and toxicity due to pelvic radiotherapy in endometrial cancer. International Journal of Gynecological Cancer. 2024;34:A180-A181. doi:10.1136/ijgc-2024- ESGO.3403.Hsieh K, Bloom JR, Dickstein DR, et al. Risk-Tailoring Radiotherapy for Endometrial Cancer: A Narrative Review. Cancers. 2024;16(7). doi:10.3390/cancers16071346 Keywords: endometrial cancer, obesity, toxicities
Proffered Paper 3556
Updates on prospective phase III trial of standard of care therapy with/without SABR for recurrent ovarian cancer (SABR- ROC, KGOG 3064/KROG 2204) Won Hee Lee 1 , Yong Bae Kim 1,2 , Sangjoon Park 1 , Yun Hwan Kim 2 , Hee Seung Kim 2 , Dae- Yeon Kim 2 1 Korean Radiation Oncology Group, Korean Radiation Oncology Group, Seoul, Korea, Republic of. 2 Korean Gynecologic Oncologic Group, Korean Gynecologic Oncologic Group, Seoul, Korea, Republic of Purpose/Objective: This ongoing phase III trial evaluates whether adding stereotactic ablative radiotherapy (SABR) improves 3-year overall survival in patients with recurrent ovarian cancer. In parallel, a pattern-of-care survey was conducted to assess real-world perception and implementation of SABR in recurrent ovarian cancer. Material/Methods: Patients with pathologically confirmed epithelial ovarian cancer who completed initial standard treatment are eligible. Up to ten metastatic lesions with maximum tumor diameter ≤ 5 cm are allowed. Participants are randomized in a 1:2 ratio into Arm 1 (standard salvage therapy alone) or Arm 2 (standard therapy plus SABR). Stratification occurs by (1) number of favorable factors (platinum sensitivity, no ascites, normal CA125, ECOG 0–1; 0–3 vs. 4), (2) recurrence site (with vs. without lymph-node involvement), and (3) PARP inhibitor use. The target enrollment is 180 patients. SABR is delivered in one to ten fractions. Results: To date, 175 patients (97.2%) have been enrolled. At the Data Safety Monitoring Board (DSMB) meeting in February 2025, 139 patients had been enrolled and 24 had discontinued, 16 from Arm 1 and 8 from Arm 2. The predominant reason for discontinuation was withdrawal of consent,
Made with FlippingBook - Share PDF online